QUOTE AND NEWS
StreetInsider.com  May 9  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Sunesis+Pharmaceuticals+%28SNSS%29+Posts+Mixed+Q1+Results/8320600.html for the full story.
StreetInsider.com  Apr 11  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Equity+Offerings/Sunesis+Pharma+%28SNSS%29+Files+%24150M+Mixed+Shelf/8246712.html for the full story.
StreetInsider.com  Apr 10  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Equity+Offerings/Sunesis+Pharmaceuticals+%28SNSS%29+Raises+Equity+Deal+with+Cantor+by+%2430M/8246318.html for the full story.
StreetInsider.com  Mar 13  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Sunesis+Pharmaceuticals+%28SNSS%29+Posts+Q4+Loss+of+20cShare/8180346.html for the full story.
Benzinga  Jan 15  Comment 
Credit Suisse initiated coverage on Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) with an Outperform rating and a $7.00 price target. Credit Suisse commented, "SNSS is a binary risk stock for which upside potential and probability of success are...
StreetInsider.com  Nov 8  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Sunesis+Pharmaceuticals+%28SNSS%29+Misses+Q3+Views/7856099.html for the full story.
StreetInsider.com  Oct 2  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Management+Changes/Sunesis+Pharma+%28SNSS%29+Announces+Two+Key+Promotions/7764795.html for the full story.
Benzinga  Sep 20  Comment 
Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced the closing of two previously disclosed financings. Royalty Pharma has invested $25.0 million under its royalty arrangement with Sunesis, and, in a separate transaction, a syndicate of...
StreetInsider.com  Sep 20  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Sunesis+Pharma+%28SNSS%29+Closes+Two+Financing+Agreements/7739977.html for the full story.
StreetInsider.com  Sep 13  Comment 
This report is an intraday check of some of the more notable stocks that have hit a 52-week high or low so far today. 52-Week High: Neuralstem, Inc. (AMEX: CUR) high of $1.96. Neuralstem ripping today following data from a study of NSI-566 on...





 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki